Newsletter Archive
-
03.06.24 -- Big Pharma Big On ADCs
3/6/2024
03/06/24 Life Science Leader Newsletter
-
03.04.24 -- Companies To Watch: Antiva Biosciences
3/4/2024
03/04/24 Life Science Leader Newsletter
-
03.04.24 -- A Patient- And Planet-Centric Approach To Enhancing Medicines In Development
3/4/2024
03/04/24 Life Science Leader Newsletter
-
03.01.24 -- State Of The Orphan Space
3/1/2024
03/01/24 Life Science Leader Newsletter
-
02.29.24 -- Enhancing Drug Development Outcomes Through Early Assessment Strategies
2/29/2024
02/29/24 Life Science Leader Newsletter
-
02.28.24 -- Pros And Cons Of Copromotion
2/28/2024
02/28/24 Life Science Leader Newsletter
-
02.26.24 -- Ruthless Resourcing Rules For CEOs
2/26/2024
02/26/24 Life Science Leader Newsletter
-
02.23.24 -- No Playbook For Leqembi: Eisai's Long Game In Alzheimer's Disease
2/23/2024
02/23/24 Life Science Leader Newsletter
-
02.21.24 -- Addimmune's Quest For A Functional HIV Cure
2/21/2024
02/21/24 Life Science Leader Newsletter
-
02.21.24 -- Nanoparticle Enabled Formulation And Drug Delivery Solutions
2/21/2024
02/21/24 Life Science Leader Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more